Cardiac Biotech Solutions Profit Margin

The latest profit margin for CBSC is -578.04% as of June 2026. That compares with -2145.81% in the prior-year period — up 73.1% year over year. That is below the sector sector average of 13.09%. Investors often review this figure alongside Cardiac Biotech Solutions's historical trend and sector peers before judging valuation or financial health.

Over the past year, CBSC's profit margin moved from -2145.81% to -578.04% — a 73.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Cardiac Biotech Solutions's valuation or profitability profile.

Against its sector companies, CBSC currently prints -578.04% for profit margin, while the sector average sits near 13.09%. That is roughly 4516.4% below the sector mean. Large gaps often invite a closer look at Cardiac Biotech Solutions's growth, margins, and balance sheet.

Profit Margin shows how effectively Cardiac Biotech Solutions converts resources into returns. At -578.04%, CBSC may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -2145.81% in the prior-year period — up 73.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CBSC's profit margin (-578.04%), review year-over-year change from -2145.81%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.